Literature DB >> 16151477

Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination.

J Steitz1, D Tormo, D Schweichel, T Tüting.   

Abstract

Optimal strategies for antigen-specific melanoma vaccination are currently being defined in experimental mouse models. Using a single H2-K(b)-binding peptide epitope derived from the melanosomal enzyme tyrosinase-related protein 2 (TRP2) in C57BL/6 mice, we show that adenovirus-transduced dendritic cells (DC) are clearly superior to peptide-pulsed DC for the induction of CD8+ T cells and antimelanoma immunity. Vaccine efficacy strictly depended on the presence of linked CD4+ T-cell help during the priming but not the effector phase of the immune response. These results provide important information for the translation of melanoma vaccine strategy in future clinical applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16151477     DOI: 10.1038/sj.cgt.7700894

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  7 in total

1.  Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

Authors:  Basav N Hangalapura; Dinja Oosterhoff; Tarun Gupta; Jan de Groot; Pepijn G J T B Wijnands; Victor W van Beusechem; Joke den Haan; Thomas Tüting; Alfons J M van den Eertwegh; David T Curiel; Rik J Scheper; Tanja D de Gruijl
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

2.  Cationic nanoparticles enhance T cell tumor infiltration and antitumor immune responses to a melanoma vaccine.

Authors:  Rasheid Smith; Emad I Wafa; Sean M Geary; Kareem Ebeid; Suhaila O Alhaj-Suliman; Aliasger K Salem
Journal:  Sci Adv       Date:  2022-07-20       Impact factor: 14.957

3.  Dendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity.

Authors:  Sheng Zhang; Weiyi Huang
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-26       Impact factor: 4.553

4.  Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity.

Authors:  Jeanette E Boudreau; Byram W Bridle; Kyle B Stephenson; Kristina M Jenkins; Jérôme Brunellière; Jonathan L Bramson; Brian D Lichty; Yonghong Wan
Journal:  Mol Ther       Date:  2009-04-28       Impact factor: 11.454

5.  Monitoring of in vivo function of superparamagnetic iron oxide labelled murine dendritic cells during anti-tumour vaccination.

Authors:  Richard Tavaré; Pervinder Sagoo; Gopal Varama; Yakup Tanriver; Alice Warely; Sandra S Diebold; Richard Southworth; Tobias Schaeffter; Robert I Lechler; Reza Razavi; Giovanna Lombardi; Gregory E D Mullen
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

6.  Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.

Authors:  T Osada; X Y Yang; Z C Hartman; O Glass; B L Hodges; D Niedzwiecki; M A Morse; H K Lyerly; A Amalfitano; T M Clay
Journal:  Cancer Gene Ther       Date:  2009-02-20       Impact factor: 5.987

7.  Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials.

Authors:  O V Markov; N L Mironova; V V Vlassov; M A Zenkova
Journal:  Acta Naturae       Date:  2017 Jul-Sep       Impact factor: 1.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.